Canaccord Genuity analyst John Young CFA has maintained their neutral stance on STAA stock, giving a Hold rating yesterday.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
John Young CFA has given his Hold rating due to a combination of factors surrounding the recent developments in the merger agreement between Alcon and Staar Surgical. The amended merger agreement increased the acquisition price to $30.75, which represents a significant premium over Staar’s previous stock prices. This adjustment, along with changes to executive compensation, appears to address shareholder concerns and could influence proxy advisory firms to support the merger.
Despite the increased bid, the valuation of $30.75 per share translates to a 4.4x EV/Sales multiple, which is only slightly above the average for similar companies in the Med-Tech sector. The lack of alternative acquisition proposals during the “go-shop” period suggests limited interest from other potential buyers. These factors contribute to the decision to maintain a Hold rating, as the current offer price aligns with the adjusted price target, reflecting a balanced risk-reward scenario for investors.